As leaders across the United States consider options to reduce healthcare costs, they must ensure that well-intended reforms do not produce unintended harm — particularly to patients, regional economies and the future of medical innovation.

While we fully support the goal of improving affordability for American patients, Most Favored Nation (MFN) policies-that tie U.S. drug prices to those in foreign countries — risk creating significant disincentives for research, restricting access to advanced therapies and destabilizing emerging life sciences economies like that of the Hudson Valley.

MFN-style pricing models could inadvertently reduce the availability of new and innovative therapies for U.S. patients. Because many peer countries impose aggressive government price controls that do not reflect the true cost of developing breakthrough treatments, forcing U.S. manufacturers to adhere to these benchmarks would make continued investment in high-risk, high-reward R&D far less viable.

These policies will have economic impacts here at home. The Hudson Valley is a rising national center for life sciences and biomedical innovation. We have made substantial public and private investments to support this sector, which includes pharmaceutical and biotech companies, academic research institutions, medical device firms, and hospital systems. Institutions such as New York Medical........

© The Leader